177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with progressive midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial - Strosberg, JR; Caplin, ME; Kunz, PL (Lancet Oncol, 2021)